Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Emodin suppresses proliferation, migration and invasion in ovarian cancer cells by down regulating ILK in vitro and in vivo.

Lu J, Xu Y, Zhao Z, Ke X, Wei X, Kang J, Zong X, Mao H, Liu P.

Onco Targets Ther. 2017 Jul 19;10:3579-3589. doi: 10.2147/OTT.S138217. eCollection 2017.

2.

Post-translational modification of the membrane type 1 matrix metalloproteinase (MT1-MMP) cytoplasmic tail impacts ovarian cancer multicellular aggregate dynamics.

Yang J, Kasberg WC, Celo A, Liang Z, Quispe K, Stack MS.

J Biol Chem. 2017 Aug 11;292(32):13111-13121. doi: 10.1074/jbc.M117.800904. Epub 2017 Jun 27.

PMID:
28655772
3.

Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection.

Yan Q, Luo H, Wang B, Sui W, Zou G, Chen H, Zou H.

Exp Ther Med. 2017 May;13(5):2217-2224. doi: 10.3892/etm.2017.4261. Epub 2017 Mar 24.

4.

Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix.

Mekhdjian AH, Kai F, Rubashkin MG, Prahl LS, Przybyla LM, McGregor AL, Bell ES, Barnes JM, DuFort CC, Ou G, Chang AC, Cassereau L, Tan SJ, Pickup MW, Lakins JN, Ye X, Davidson MW, Lammerding J, Odde DJ, Dunn AR, Weaver VM.

Mol Biol Cell. 2017 Jun 1;28(11):1467-1488. doi: 10.1091/mbc.E16-09-0654. Epub 2017 Apr 5.

5.

Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.

Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P.

Sci Rep. 2017 Mar 6;7:43710. doi: 10.1038/srep43710.

6.

Research advances on structure and biological functions of integrins.

Pan L, Zhao Y, Yuan Z, Qin G.

Springerplus. 2016 Jul 15;5(1):1094. doi: 10.1186/s40064-016-2502-0. eCollection 2016. Review.

7.

RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis.

Alesi GN, Jin L, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Kang S.

Oncogene. 2016 Oct 13;35(41):5412-5421. doi: 10.1038/onc.2016.79. Epub 2016 Apr 4.

8.

Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells.

Bruney L, Liu Y, Grisoli A, Ravosa MJ, Stack MS.

Oncotarget. 2016 Apr 19;7(16):21968-81. doi: 10.18632/oncotarget.7880.

9.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

10.

E-spun composite fibers of collagen and dragline silk protein: fiber mechanics, biocompatibility, and application in stem cell differentiation.

Zhu B, Li W, Lewis RV, Segre CU, Wang R.

Biomacromolecules. 2015 Jan 12;16(1):202-13. doi: 10.1021/bm501403f. Epub 2014 Dec 1.

11.

An increase in integrin-linked kinase non-canonically confers NF-κB-mediated growth advantages to gastric cancer cells by activating ERK1/2.

Tseng PC, Chen CL, Shan YS, Chang WT, Liu HS, Hong TM, Hsieh CY, Lin SH, Lin CF.

Cell Commun Signal. 2014 Nov 15;12:69. doi: 10.1186/s12964-014-0069-3.

12.

Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE, Wan Y.

Cell Mol Life Sci. 2014 Apr;71(8):1549. doi: 10.1007/s00018-013-1376-3. Retraction in: Cell Mol Life Sci. 2014 Apr;71(8):1549.

13.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Aug;61(8):1486-9. doi: 10.1002/pbc.24989. Epub 2014 Feb 20.

14.

LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.

Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KLB, Rauscher FJ 3rd.

Cancer Res. 2014 Mar 1;74(5):1390-1403. doi: 10.1158/0008-5472.CAN-13-1275.

15.

Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.

Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CS.

PLoS One. 2013 Jun 19;8(6):e67149. doi: 10.1371/journal.pone.0067149. Print 2013.

16.

Effects of oleic acid on cell proliferation through an integrin-linked kinase signaling pathway in 786-O renal cell carcinoma cells.

Liu Z, Xiao Y, Yuan Y, Zhang X, Qin C, Xie J, Hao Y, Xu T, Wang X.

Oncol Lett. 2013 Apr;5(4):1395-1399. Epub 2013 Jan 29.

17.

Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell adhesion and survival.

Leyme A, Bourd-Boittin K, Bonnier D, Falconer A, Arlot-Bonnemains Y, Théret N.

Mol Biol Cell. 2012 Sep;23(17):3461-72. doi: 10.1091/mbc.E11-11-0918. Epub 2012 Jul 5.

18.

Role of estrogen receptor signaling in breast cancer metastasis.

Saha Roy S, Vadlamudi RK.

Int J Breast Cancer. 2012;2012:654698. doi: 10.1155/2012/654698. Epub 2011 Dec 19.

19.

Protection against Fas-induced fulminant hepatic failure in liver specific integrin linked kinase knockout mice.

Donthamsetty S, Mars WM, Orr A, Wu C, Michalopoulos GK.

Comp Hepatol. 2011 Nov 21;10:11. doi: 10.1186/1476-5926-10-11.

20.

Significance of talin in cancer progression and metastasis.

Desiniotis A, Kyprianou N.

Int Rev Cell Mol Biol. 2011;289:117-47. doi: 10.1016/B978-0-12-386039-2.00004-3. Review.

Supplemental Content

Support Center